Rapport Therapeutics Inc
RAPP14.040USD
-0.110-0.78%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
14.040USD+14.040After-hours (ET)
512.42MMarket Cap
LossP/E TTM
Rapport Therapeutics Inc
14.040
-0.110-0.78%
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
-14.89%-20.24M
-39.48%-14.45M
-202.64%-16.41M
-147.80%-16.35M
-266.90%-17.61M
---10.36M
---5.42M
---6.60M
---4.80M
Net income from continuing operations
-6.15%-24.06M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
---13.52M
---8.71M
---6.41M
---6.15M
Operating gains losses
60.53%244.00K
390.57%260.00K
852.17%219.00K
890.48%208.00K
913.33%152.00K
--53.00K
--23.00K
--21.00K
--15.00K
Other non-cash items
-100.38%-25.00K
319.08%725.00K
-1614.29%-1.80M
---670.00K
537.67%6.57M
--173.00K
--119.00K
--0.00
--1.03M
Change in working capital
86.28%-433.00K
-31.02%1.34M
-120.88%-477.00K
89.34%-123.00K
-648.10%-3.16M
--1.94M
--2.28M
---1.15M
---422.00K
-Change in prepaid expenses
60.14%-825.00K
99.36%-12.00K
-232.28%-672.00K
173.95%900.00K
-241.58%-2.07M
---1.89M
--508.00K
---1.22M
---606.00K
-Change in other current assets
-288.89%-51.00K
127.83%32.00K
-100.00%0.00
4.35%24.00K
115.70%27.00K
---115.00K
--24.00K
--23.00K
---172.00K
Cash from non-recurring investing activities
Cash from operating activities
-14.89%-20.24M
-39.48%-14.45M
-202.64%-16.41M
-147.80%-16.35M
-266.90%-17.61M
---10.36M
---5.42M
---6.60M
---4.80M
Investing cash flow
Net cash from continuing investing activities
-72.85%291.00K
-84.27%226.00K
169.23%140.00K
1024.42%967.00K
1657.38%1.07M
--1.44M
--52.00K
--86.00K
--61.00K
Capital expenditures
-72.85%291.00K
-84.27%226.00K
169.23%140.00K
1024.42%967.00K
1657.38%1.07M
--1.44M
--52.00K
--86.00K
--61.00K
Net cash flow from disposal of fixed assets
-72.85%291.00K
-84.27%226.00K
169.23%140.00K
1024.42%967.00K
1657.38%1.07M
--1.44M
--52.00K
--86.00K
--61.00K
Net cash flow from investment products
152.19%21.32M
141.64%32.16M
---52.90M
---106.14M
---40.85M
---77.22M
----
----
--0.00
Cash from non-current investing activities
Net cash flow from investing activities
150.16%21.03M
140.59%31.93M
-101901.92%-53.04M
-124439.53%-107.10M
-68631.15%-41.93M
---78.66M
---52.00K
---86.00K
---61.00K
Financing cash flow
Cash flow from continuous financing activities
-99.99%5.00K
105.00%7.00K
-101.63%-1.39M
177158.89%159.35M
6.09%63.66M
---140.00K
--85.36M
---90.00K
--60.01M
Net cash flow from common stock issuance/repurchase
---1.00K
100.00%0.00
-2681.48%-1.39M
530133.33%159.07M
-100.00%0.00
---6.00K
--54.00K
--30.00K
--24.00K
Net cash flow from preferred stock issuance/repurchase
-100.00%0.00
--0.00
-100.00%0.00
----
--63.94M
----
--85.31M
----
--0.00
Proceeds from stock option exercised by employees
--6.00K
--7.00K
----
----
----
----
----
----
----
Net cash flow from other financing activities
100.00%0.00
----
----
335.83%283.00K
-100.47%-283.00K
---134.00K
--0.00
---120.00K
--59.98M
Net cash from non-recurrent financing activities
Net cash from financing activities
-99.99%5.00K
105.00%7.00K
-101.63%-1.39M
177158.89%159.35M
6.09%63.66M
---140.00K
--85.36M
---90.00K
--60.01M
Net cash flow
Beginning cash balance
-18.99%56.91M
-75.27%39.42M
38.65%110.27M
-13.82%74.37M
125.47%70.25M
--159.41M
--79.53M
--86.30M
--31.16M
Current period cash flow changes
-80.60%799.00K
119.62%17.49M
-188.69%-70.85M
629.85%35.90M
-92.53%4.12M
---89.16M
--79.88M
---6.78M
--55.14M
Ending cash balance
-22.40%57.71M
-18.99%56.91M
-75.27%39.42M
38.65%110.27M
-13.82%74.37M
--70.25M
--159.41M
--79.53M
--86.30M
Free cash flow
-9.85%-20.53M
-24.40%-14.67M
-202.32%-16.55M
-159.07%-17.32M
-284.35%-18.69M
---11.79M
---5.48M
---6.69M
---4.86M
Currency unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
Audit opinions
--
--
--
--
--
--
--
--
--
